Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Obese Chronic Kidney Disease
NCT02252081Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in metabolic syndrome (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Change in Leptin to Adiponectin Ratio at 16 weeks. Started Oct 2014; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02252081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252081.